Optimal Treatment Strategies of Clozapine for Refractory Schizophrenia. 2016

Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
Department of Psychosomatic Disorders, the Sixth People's Hospital of Hebei Province, Baoding, Hebei 071000, China.

Objective To systematically evaluate the efficacy of clozapine combined with other antipsychotic drugs in the treatment of refractory schizophrenia. Methods We searched Medline, EMBASE, and China Biology Medicine databases in both English and Chinese for randomized controlled trials, quasi-randomization controlled trials, and clinical controlled trials concerning the combinations of clozapine with other antipsychotic drugs for refractory schizophrenia. Quality assessment and data extraction were conducted with the Cochrane collaboration's RevMan 5.3 software. Results Totally 47 trials met the inclusion criteria, in which clozapine was combined with risperidone, aripiprazole, sulpiride, ziprasidone, modified electroconvulsive therapy, valproate, or lithium carbonate, respectively. Analysis showed that most combination strategies were superior to clozapoine alone (P<0.05), except for the combination with lithium carbonate(8 weeks: RR=1.27, 95%CI=0.82-1.97,P=0.28; 12 weeks: RR=1.53, 95% CI=0.45-5.13, P=0.49). Conclusion Reasonable combination of clozapine with other drugs may improve the therapeutic effectiveness and reduce adverse reactions and thus can be effectively used for treating refractory schizophrenia.

UI MeSH Term Description Entries
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
January 1998, Indian journal of psychiatry,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
July 1999, The Journal of clinical psychiatry,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
December 2014, Journal of clinical psychopharmacology,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
August 2018, The Australian and New Zealand journal of psychiatry,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
April 1999, Acta psychiatrica Scandinavica,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
May 2004, The American journal of psychiatry,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
June 1993, Schizophrenia research,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
April 2006, The New England journal of medicine,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
April 2006, The New England journal of medicine,
Yuan-Yuan Li, and Yun-Shu Zhang, and Jian Wang, and Ke-Qing Li, and Hong-Ying Wang
April 2006, The New England journal of medicine,
Copied contents to your clipboard!